PMID- 28321818
OWN - NLM
STAT- MEDLINE
DCOM- 20170912
LR  - 20231102
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 995
DP  - 2017
TI  - Skin Reactions to Immune Checkpoint Inhibitors.
PG  - 175-184
LID - 10.1007/978-3-319-53156-4_9 [doi]
AB  - The novelty of immune checkpoint inhibitors has only recently led to the 
      characterization of cutaneous adverse events (AEs). This, along with the 
      substantial rate of cutaneous reactions, has left many clinicians without 
      sufficient familiarity to diagnose and treat. In the following chapter, we will 
      review the categories of these drugs, common cutaneous effects, their grading, 
      and management options.
FAU - Patel, Anisha B
AU  - Patel AB
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      1400 Pressler Street, Unit 1452, Houston, TX, 77030, USA. 
      APatel11@mdanderson.org.
FAU - Pacha, Omar
AU  - Pacha O
AD  - Department of Dermatology, The University of Texas MD Anderson Cancer Center, 
      1400 Pressler Street, Unit 1452, Houston, TX, 77030, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Antibodies, Monoclonal/*adverse effects
MH  - Antineoplastic Agents/*adverse effects
MH  - Biomarkers, Tumor/*antagonists & inhibitors/immunology/metabolism
MH  - Drug Eruptions/diagnosis/*etiology/therapy
MH  - Humans
MH  - Immunotherapy/*adverse effects/methods
MH  - Neoplasms/*drug therapy/immunology/metabolism/pathology
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Signal Transduction/drug effects
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anti-CTLA4
OT  - Anti-PD1
OT  - Dermatitis
OT  - Immune checkpoint inhibitors
OT  - Immunotherapy
OT  - Ipilimumab
OT  - Nivolumab
OT  - Pruritus
OT  - Rash
EDAT- 2017/03/23 06:00
MHDA- 2017/09/13 06:00
CRDT- 2017/03/22 06:00
PHST- 2017/03/22 06:00 [entrez]
PHST- 2017/03/23 06:00 [pubmed]
PHST- 2017/09/13 06:00 [medline]
AID - 10.1007/978-3-319-53156-4_9 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2017;995:175-184. doi: 10.1007/978-3-319-53156-4_9.